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1 G 38 1082/10 II B WDS 1 1 PR 1 >4 200 130 18 20 12 15 32 11 + 0 0
2 M 42 1121/10 II B MDS 2 1 PD >4
3 L 50 1330/10 IIB WDS 1 2 PR 2 >4 260 145 16 17 5 4 28 0 + 0 0
4 M 45 1329/10 IB 2 PDS 3 2 PR 1 >4 280 135 24 16 5 11 34 34 + 0 0
5 V 37 1421/10 II B PDS 3 2 PR 1 >4 320 190 20 18 7 10 26 28 + 0 0
6 A 55 1506/10 IIB PDS 3 2 PR 1 <4 200 130 18 22 8 6 32 4 + 0 0
7 S 56 1547/10 IIB smS 3 1 CR >4 150 120 22 20 6 7 30 0 - 0 0
8 D 38 30/11 IIB WDS 1 2 PR 1 >4 400 200 18 16 3 5 24 28 + 0 0
9 Y 38 198/11 IIB PDS 3 2 SD >4
10 V 66 295/11 IIB WDS 1 2 CR >4 240 100 22 17 8 7 22 0 - 0 0
11 K 34 297/11 IIB MDS 2 1 PR1 >4 180 110 24 20 7 8 34 14 + 0 0
12 P 35 311/11 IIB PDS 3 2 SD <4
13 S 40 370/11 IIB WDS 1 1 CR >4 340 130 22 24 10 9 35 0 - 0 0
14 D 36 406/11 IIB PDS 3 2 SD >4
15 S 50 432/11 IIB MDS 2 2 PR2 >4 280 120 24 26 8 9 33 0 + 0 0
16 V 50 531/11 IB 2 WDS 1 1 PR1 >4 240 100 22 24 7 9 35 8 + 0 0
17 T 40 541/11 IIB MDS 2 2 SD <4
18 D 47 731/11 IIB PDS 3 1 CR >4 250 140 26 24 7 8 36 0 - 0 0
19 S 47 854/11 IIB Lcs 1 2 PR1 >4 150 120 24 22 8 10 28 4 + 0 0
20 L 55 932/11 IIB WDS 1 1 PR1 >4 600 200 24 14 12 10 34 0 + 0 0
21 S 65 972/11 IIB MDS 2 2 PR1 >4 750 210 16 18 10 12 28 14 + 6 8
22 S 32 1000/11 IB2 MDS 2 1 CR <4 240 90 24 26 6 8 30 0 - 0 0
23 M 48 1033/11 IIB smS 3 2 PR1 >4 320 130 22 27 8 10 28 4 + 0 0
24 L 37 1066/11 IIA 2 WDS 1 1 PD >4
25 B 45 1178/11 IB2 MDS 2 2 PR1 >4 700 180 24 22 9 7 30 0 - 4 0
MASTER CHART
26 M 40 1177/11 IIA 2 PDS 3 1 PR2 >4 240 90 24 21 9 8 28 0 - 0 0
27 S 50 1162/11 IB 1 MDS 2 2 SD >4
28 M 50 1182/11 II B WDS 1 2 PR1 >4 320 140 22 26 8 11 35 12 + 0 0
29 S 48 1195/11 IIB MDS 2 1 CR >4 140 95 26 24 7 6 30 0 - 0 0
30 N 52 1308/11 IIB PDS 3 2 SD >4
31 M 52 1317/11 IIA 2 Lcs 1 1 SD <4
32 K 38 1347/11 IB2 MDS 2 1 PR1 >4 400 150 22 28 9 11 28 11 + 0 0
33 A 41 1348/11 IIB PDS 3 2 PR1 >4 260 130 24 26 12 9 32 8 + 0 0
34 M 40 1386/11 IB2 WDS 1 1 CR >4 320 90 27 21 7 8 26 0 - 0 0
35 M 63 1376/11 IIA 2 smS 3 2 PR1 >4 290 160 24 18 8 12 30 14 + 0 0
36 V 61 34/12 IB 2 MDS 2 1 PR 1 >4 320 140 28 22 7 11 38 0 + 0 0
37 K 48 266/12 IIB MDS 2 1 PR1 >4 270 120 24 22 6 9 28 8 + 0 0
38 V 40 287/12 IIB PDS 3 1 CR <4 200 90 26 24 7 8 30 0 - 0 0
39 P 58 313/12 IIB WDS 1 1 CR >4 270 140 24 24 8 10 28 0 - 0 0
40 V 48 331/12 IIA 2 Lcs 1 1 CR >4 220 100 22 25 7 9 33 0 - 0 0
41 P 42 432/12 IIB PDS 3 2 SD >4
42 L 45 525/12 IB2 MDS 2 2 PR1 >4 340 140 20 24 8 9 28 0 + 0 0
43 L 55 639/12 IIB WDS 1 2 SD >4
44 S 55 739/12 IIB PDS 3 1 CR >4 270 120 24 30 9 11 27 0 - 0 0
45 T 43 763/12 IIB MDS 2 1 CR >4 180 95 26 22 8 9 30 0 - 0 0
46 V 48 854/12 IIB PDS 3 1 PR 1 >4 400 140 24 20 11 13 34 16 + 8 6
47 V 36 873/12 IIB WDS 1 2 PR2 <4 220 130 22 24 9 8 26 8 + 0 0
48 M 36 1016/12 IB2 MDS 2 1 CR >4 1200 220 24 20 7 8 30 0 - 0 0
49 A 47 1050/12 IIB PDS 3 1 SD >4
50 J 48 1076/12 IIB WDS 1 2 SD >4
51 S 46 1077/12 IIA2 MDS 2 2 SD >4
52 A 40 1081/12 IB2 PDS 3 1 SD >4
53 M 60 1085/12 IIB MDS 2 2 CR >4 240 100 24 20 6 8 28 0 - 0 0
54 M 62 1095/12 IIB PDS 3 1 SD >4
55 A 42 2008/12 IIB MDS 2 2 CR >4 340 130 26 24 9 8 34 0 - 0 0
56 L 52 2014/12 IIB PDS 3 2 PR 1 <4 200 130 18 22 8 6 32 4 + 0 0
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INTRODUCTION 
 
EPIDEMIOLOGY OF CERVICAL CANCER WORLDWIDE 
Cervical cancer is among the commonest cancers affecting women worldwide. It is the 
seventh commonest cancer affecting an estimated 530,000 new women in 2008, 
accounting for 4.2% among all cancers [1]. It is the third commonest cancer among 
women causing 8.8% of all cancers in women. In developing countries, it increases to 
13% of all cancers in women [1]. The incidence and mortality rates are higher in low and 
middle income countries. Even in these countries, the highest incidence and mortality 
rates are seen in the low socio-economic groups which further exemplify the health 
inequity of this disease [2].  
 
Cervical cancer tops the list among cancers among women in certain parts of Asia and 
Africa. The low risk regions are Western Asia, North America, Australia and New 
Zealand. Overall, the mortality rate is 52%.The estimated death due to cervical cancer 
was 275000 in 2008 and 88% of these occurred in developing countries [1] .There is a 
seventeen fold difference in mortality due to cervical cancer among different 
regions of the world [2].  
 
 
 
 
Worldwide distribution of Cervical Cancer  
 
 
 
 
 
 
 
 
 
  
 
 
THE BURDEN OF CERVICAL CANCER IN INDIA  
Cervical cancer has been highly prevalent among women in India over the past few 
decades. India accounts for one fourth of the global burden of this disease.  
Two population based cancer registries in our country have recorded highest incidence 
rates for cervical cancer. In the rest of the population based cancer registries, it is 
second only to breast cancer in incidence. The burden of cervical cancer in India is 
disproportionately high [3]. Cervical cancer is the third leading cause of cancer mortality. 
It accounts for 10% of all cancer mortality in India. Almost 26% of all cancer deaths in 
women are caused by cervical cancer. 
 
Chennai has the highest age adjusted incidence rates while Thiruvanathapuram in 
Kerala has the lowest age adjusted incidence rate .North eastern districts of Tamilnadu 
show a higher incidence compared to other districts in the state [ICMR]. 
 
Cervical Cancer Incidence in India 
 
 
The highest incidence of cervical cancer in our country is found in women in their late 
40s and 50s. 
The prevalence is higher in rural India and among women of low socio economic status. 
This may be due to lack of awareness of risk factors of the disease and poor access to 
health care facilities. Women from low socio economic status show poor compliance to 
treatment and follow up which further increases the mortality and morbidity from the 
disease.  
 
  
Despite having had a diagnosis of cervical cancer, around 40% of patients registered in 
the Hospital Based Cancer Registries in Bangalore, Chennai and Mumbai did not 
complete their treatment at the reporting institution. Thus the most disadvantaged 
sections of Indian society are the worst victims of this debilitating disease.  
 
Cervical cancer screening programs have reduced mortality and morbidity from the 
disease in the developed world but  these success stories are not applicable to 
developing countries like India because  cytology based screening programmes 
demand facilities, expertise and equipment. Hence, death from this disease remains 
high in middle income countries, including India. 
 
ECONOMIC BURDEN OF CERVICAL CANCER  
Cervical cancer patients lose a large part of their productive life because of  long 
standing disability and early death. This disease is responsible for 2.7million (age 
weighted) Years of Life Lost (YLL) worldwide among women between the ages of 25 
and 64, out of which 2.4million occur in developing countries. The Years of Life Lost 
(YLL) due to cervical cancer is greater than that caused by any other cancer in India. It 
accounts for 4% of total YYLs due to all causes in India. In India, the Years of Life Lost 
(YLL) due to cervical cancer were 936.3 in 2000, being among the highest in the world 
[4] .The high medical expenses and the mortality burden has a significant impact on the 
economic structure of families which in turn affects the individual and community at 
large. [4]  
Hence it becomes imperative to identify new prevention strategies to reduce the 
overall risk of cervical cancer, to design new methodologies to detect cancer 
early and to explore newer treatment options to improve the therapeutic outcome 
of cervical cancers. 
 Table showing Years of Life Lost 
 
  
RISK FACTORS FOR CERVICAL CANCER  
 
Human Papilloma Virus:  
Cervical cancer behaves like a sexually transmitted disease in terms of risk factors.  
Several studies have shown that the causative agent of cervical cancer is infection with 
human papilloma virus [HPV].  HPV DNA is found in the majority of patients with 
invasive cervical cancer. More than 40 HPV types can infect the cervix.70% of cervical 
cancers are caused by HPV 16 and 18. The remaining cancers are caused by other 
high risk strains namely 31, 33, 35 etc. [5]. HPV infection occurs in 50% of men and 
women who are sexually active.  
 
The series of steps involved in progression of HPV infection to invasive cancer are:  
[1]HPV transmission 
[2]Acute HPV infection 
[3]Persistent HPV infection causing precancerous lesions 
[4]Invasive cervical cancer 
 
HPV infection resolves spontaneously in majority of women. Persistent infections are 
found in 3 – 10% of women and these women are at high risk of developing cervical 
cancer. In India, invasive cervical cancers are associated with HPV 16/18 in 82.5% of 
cases. Women with HPV infection have a 500 fold increase in the odds of having 
cervical cancer compared to women with no HPV infection [5].  
 Female sexual behavior  
1. Age at first intercourse - Women who start their sexual life at an early age 
particularly before 16 years are at higher risk (2.4 fold increased risk) of 
developing cancer cervix [6]  
2. Multiple sexual partners – women with promiscuous sexual behavior are at 
higher risk of developing cervical cancer. The risk of acquiring cervical cancer 
doubles when the number of sexual partners is more than 6.  
3. Parity - Risk factors related to parity include age at first child birth and multiparity.  
Male sexual behavior (high risk male)  
. High risk male sexual habits, the presence of which is associated with a higher 
incidence of cancer cervix in their spouses are  
1. Promiscuous behavior with >3 extra marital partners  
2. History of sexually transmitted disease  
3. History of penile cancer (increases risk of cancer cervix in wife by 3 – 6 times)[6]  
 
Lower socio-economic group  
 Women from a lower socio-economic group have a higher incidence (about 3 fold) of 
cervical malignancy due to early marriage, early onset of sexual life and lack of genital 
hygiene.  
 
Smoking  
Smoking appears to double the risk of developing cervical cancer [7]. Smoking 
constituents have been detected in cervical mucus. Levels of nicotine were increased 
forty-fold and the major metabolite of nicotine, nicotinine levels were increased four-fold 
in the cervical mucus of women with CIN, compared to serum levels [8]. It was found 
that there was increased DNA damage in cervical epithelium of smokers, regardless of 
concomitant HPV infection [9]. 
 
   
OVERVIEW OF TREATMENT POLICY IN CANCER CERVIX [40, 42, 43] 
 
All the three standard modalities of oncology namely radiation, surgery and 
chemotherapy have stamped their role in the treatment of different stages of the 
disease. An overview of current treatment recommendations for carcinoma of the cevix 
are given below. 
EARLY STAGE CERVICAL CANCER  
FIGO Stage I A 
Microinvasive carcinoma (invasion ≤ 5 mm): 
Recommended work-up  
• Vaginal and rectal examination, exfoliative cytology (Papanicolaou smear), 
colposcopy, biopsy and/or endocervical curettage (ECC), conization or Loop 
electrosurgical procedure (LEEP)  
• Histopathological finding with all standard tumor parameters  
• Laboratory analyses: WBC, biochemical analyses  
• Imaging: Chest X-ray, pelvic and abdominal ultrasound 
 
Diagnosis is based on conisation 
Necessary Histo Pathologic parameters:  
•  Depth of invasion 
•  Width of the tumor 
•  Tumor differentiation  
•  Lympho-vascular space invasion (LVSI) 
•  Resection margins  
 
Microscopic stage IA disease is treated with surgery
 
Management algorithm for stage IA
 
 
 
 
  
Margins clear
ECC negative
Stage Ia1
LVSI negative 
Conization sufficient if preservation 
of fertility is desired
or
Simple (extrafascial,) hysterectomy 
with or without salpingoophorectomy
 
 (micro invasive - invasion <5mm):
Conization
Stage Ia1 with 
extensive LVSI
Stage Ia2
Conization sufficient or radical 
trachelectomy if preservation of 
fertility is desired
or
Modified radical hysterectomy 
and
Pelvic lymphadenectomy
Margins and/or
ECC positive for 
dysplasia
Repeated 
• Modified radical 
hysterectomy  if re
conisation
± pelvic 
 
 
conisation
-
is not possible
lymphadenectomy
FIGO Stage Ib – II: 
Recommended work-up 
Neccessary investigations: 
1. Vaginal and rectal examination, colposcopy,  biopsy and/or endocervical 
curettage (ECC); conization or loop electrosurgical procedure (LEEP) if needed 
for definitive diagnosis 
2. Histopathological finding with all standard tumor parameters 
3. Laboratory analyses: Complete hemogram, biochemical analyses including 
check for renal function and Hemoglobin  
4. Imaging: Chest X-ray, abdominal and pelvic ultrasound (size and position of the 
tumor and tumor volume/cervix ratio) 
Optional investigations: 
1. Pelvic Magnetic Resonance Imaging 
2. Computerized Tomography of the abdomen (PET/CT if possible) 
3. Cystoscopy 
4. Proctoscopy 
5. Intra Venous Urogram or sonographic renal examination. 
6. Involvement of the bladder or rectum should be confirmed histologically 
. In early disease surgery is preferred over RT in: 
1. Small volume disease (<4cm)  
2. Younger patients for better preservation of sexual life as it preserves a pliable 
vagina. 
3. Endocervical cancers and adenocarcinomas due to reduced response rates of 
these histologies to RT 
4.  Patients with co-existing diseases like uterine myomas, ovarian cysts and 
prolapsed due to difficulty in optimal delivery of RT.  
Advantages of surgery in early disease:  
1. Surgery is both therapeutic and a staging procedure. Based on findings in the 
post-op specimen appropriate post-op RT can be combined to enhance cure 
rates.  
2. Surgery preserves the ovaries if necessary and leaves behind a pliable vagina 
which preserves the sexual life of the patient.  
3. Psychological relief to the patient that the disease has been cured is higher with 
surgery.  
 
Radiotherapy is however also an effective alternative curative modality to surgery in 
early stage cervical cancer. 
 
  
Algorithm for stage Ib –
Radical surgery
Uterus with paracervical tissues and 
upper part of vagina 
(radical, hysterectomy) + pelvic 
lymphadenectomy
or
• Entire cervix with paracervical
tissues (radical trachelectomy) if 
fertility is desired + pelvic 
lymphadenectomy
or
• Upper part of vaginal 
cuf, paracervical tissues + pelvic 
lymphnodes in case of previous 
simple hysterectomy
* At least 2 cm distance from the 
resection margins is desirable
** In premenopausal women ovaries 
can be retained; if so tranposition is 
advised.
*** For the desision of further 
management, all neccesary
histopathologic parameters4 should 
be requested
post op management 
based on 
histopathology
(contd)
 II: 
C e r v i c a l c a n c e r
F I G O S t
a g e
I b - I I
a
Squamocellular, Adenocarcinoma, Adenosqua
mous
Neoadjuvant chemotherapy 
followed by radiation or surgery is 
an option for locally advanced  
tumors (Ib2 and IIa2) but awaits 
confirmatory evidence from 
controlled clinical trials.
Chemo
• Medical contra
• Ib2
• Anterior vaginal extension
• Invasive cancer after simple 
hysterectomy
• Choice of the patient
 
-radiation
-indications for 
surgery
/IIa2 tumors
  
 
 
 
 
 
Negative nodes
Follow up
Radical surgery
Positive nodes (1-3)
• Poorly differentiated or 
undifferentiated tumor (G3)
• LVSI present
• Primary tumor
(tumor-cervix volume) >3 cm
• Endocervical invasion
(barrel shaped cervix)
• Inadequate surgery
• Insufficient HP (if report of all 
necessary parts is missing)
Radiation
± Chemotherapy
• Positive resection margins
• Involvement of 
• Residual tumor
• Multiple positive nodes (>3) 
Concomitant
Chemo
 
parametria
-radiation
 Management of advanced stage disease: 
Cervical cancer FIGO stage IIB- IV: 
 
Recommended work-up 
1. Vaginal and rectal examination, biopsy or endocervical curettage (ECC) 
2. Histopathological finding with all standard tumor parameters 
3. Laboratory analyses: WBC, biochemical analyses including check for renal 
function and Hb   
4. Imaging: Chest X-ray, abdominal and pelvic ultrasound 
5. Pelvic Magnetic Resonance imaging, CT of the abdomen (PET/CT if possible), 
cystoscopy, rectoscopy, IVU or sonographic renal examination. Involvement of 
the bladder or rectum should   be confimed histologically  
  
Paraaortic
(=not enlarged)
Pelvic (±
+ brachytherapy
+ concomitant chemotherapy
pelvic, abdominal and chest imaging 
exclude distant metastases primary 
• Neo adjuvant chemotherapy
be offered to large bulky tumors to 
C e r v i c a l c a n c e r
F I G O s t
a g e
I I b - I V
Pelvic MRI and
Abdominal CT
nodes (PALN) 
negative
paraaortic) radiation
Stage IVa
• with vesicovaginal fistula: if 
pelvic exenteration can be 
considered
may 
downsize tumor prior to CCRT
Pelvic or paraaortic
(PALN) positive (enlarged ≥2 
cm))
CT of the lungs & mediastinum
Pelvic radiation (with 
if PALN are positive) + 
brachytherapy
chemotherapy 
Palliative pelvic 
± Palliative chemotherapy
 
nodes 
paraaortic
+ concomitant 
RT
Management of recurrence: 
Recommended work-up 
1. Vaginal and rectal examination, biopsy - histopathological confirmation of 
recurrence 
2. Laboratory analyses: WBC, biochemical analyses including check for renal 
function and Hb  
3. Imaging: Chest X-ray, pelvic and abdominal ultrasound, pelvic MRI  and CT of 
the lungs and abdomen; (PET/CT if possible) 
4. Cystoscopy, rectoscopy, IVU or sonographic renal examination 
 
 
Pelvic recurrence
No previous radiation
Options include:
• Chemo-radiation
• Neoadjuvant
chemotherapy (NACT)
• Supportive care
C e r v i c a l c a n c e r
-
r e c u r r e n c e
-
Lungs & abdominal 
CT
Previous radiation
Central pelvic
recurrence
Options include
• Radical hysterectomy 
in tumor  <2 cm 
• Pelvic exenteration
• Neoadjuvant
chemotherapy (NACT) + 
surgery
Other options if surgery 
is not possible:
• Re-irradiation 
• Neoadjuvant
chemotherapy (NACT) + 
radiation
• Systemic therapy
• Supportive care
Sidewall pelvic
recurrence
Options include:
• Resection of isolated disease
• Systemic therapy
• Supportive care
Extrapelvic
recurrence
• Systemic therapy
• Supportive care
 
Options include:
• Palliative 
radiotherapy or 
chemo-radiation
 MANAGEMENT OF LOCALLY ADVANCED CERVICAL CANCER 
 
Concomitant chemo radiotherapy remains the standard for locally advanced cervical 
cancer. An individual patient data meta analysis demonstrated an absolute 5-year 
survival benefit of 6% (from 60% to 66%) and 5-year disease-free survival benefit of 8% 
with chemo radiotherapy compared with radical RT alone.  Patients with stage IB – IIA 
had a 5 year survival benefit of 10% with chemo radiotherapy. The survival benefit was 
7% for stage IIB cancers and 3% for stage III – IVA. Mono therapy with cisplatin 
40mg/m2 weekly is the preferred regimen. However, chemo radiotherapy is associated 
with increased gastrointestinal and hematologic toxicity.  
  
NOVEL APPROACHES  
Exclusive chemoradiation is currently the gold standard of treatment in locally advanced 
cervical cancer. However, 5yr survival of patients treated for cervical cancer is still only 
around 70%. Hence there is a compelling need to improve the outcomes of locally 
advanced forms of this disease. 
This causes a concern that chemo radiation might be insufficient to eradicate bulky 
tumors. To address this issue, several different approaches like 
i. Addition of newer chemotherapeutic agents,
ii. Neoadjuvant chemotherapy
iii. Altered fractionation schedules and 
iv. Tri-modality treatments, including radio
have been investigated. 
 
Potential benefits of neoadjuvant therapy
There are several potential benefits of
i. Downsize the tumor,  
ii. Render bulky tumors (International Federation of Gynecology and Obstetrics 
[FIGO] stages IB 2, IIA 2 and IIB) safe for 
 
 
 
 
-therapy, chemotherapy and surgery, 
 
: 
 neoadjuvant chemotherapy followed by surgery
surgery 
 
 
iii. When a pelvic recurrence occurs RT would be an open option. 
iv. It can eradicate or biologically alter micro metastases 
In view of economic implications, availability of radiotherapy centres and 
radiotherapy induced morbidity, the advantages of downsizing the disease without the 
use of irradiation are tempting and open a completely new philosophy of radical 
treatment for locally advanced cervical cancer. 
Pathologic complete response rates achieved with neoadjuvant strategies have 
proven to be an important determinant of long term survival in trials investigating 
neoadjuvant modalities.  
Thus better neoadjuvant modalities would increase the pathological complete response  
rates and improve survival. 
 
PROGNOSTIC FACTORS  
Identification of factors of possible prognostic significance may help the clinician in 
tailoring treatment. Patients with a low risk of recurrence may be subjected to less 
intensive treatment whereas patients with a high risk of recurrence may be eligible for 
clinical trials.  
TUMOR FACTORS  
1. Stage of the disease has been found to be a strong prognostic factor.  As the 
stage advances, the prognosis becomes worse. Numerous studies have 
indicated tumor size as a strong prognostic indicator for both early and locally 
advanced cervical cancer.  
2. Tumor size more than 4 cm has been defined as bulky cervical cancer by FIGO 
and 10 year actuarial pelvic failure rates are found to be higher in patients with 
bulky cervical cancers. Another strong prognostic indicator is depth of invasion.  
3. Lympho vascular space invasion is a classical prognostic parameter in early 
stages.  
4. Presence of lymph node metastases has been proven to be of prognostic 
importance in several studies.  
5. Depth of tumor invasion determines the incidence of pelvic lymph node 
metastases and, in advanced stages; tumor volume determines the incidence of 
lymph node metastases.  
6. Extent of parametrial involvement was found to correlate adversely with 
survival. A retrospective study done by Kovalic et al, reported lower 10 year 
disease free survival in stage IIB disease with lateral half of parametrial 
involvement compared to medial half of parametrial involvement ( 52% Vs 68%, 
p value = 0.004). Stage IIB patients whose disease extended into the lateral 
parametrium had higher total pelvic failure rates. The 10 year disease free 
survival was lower in patients with stage IIIB cancers with bilateral parametrial 
invasion compared to unilateral parametrial invasion [10]. 
7. Histologic subtype: No significant difference in 5 year survival among patients 
with squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma 
[11]. However there are conflicting reports in the literature regarding the 
importance of histologic subtype as a predictor of overall survival in patients with 
cervical cancer. 
8. Grade of the tumor: In contrast to other epithelial malignancies where histologic 
grading is an established prognostic factor, microscopic grading of cervical 
cancers has no prognostic value [12] 
9. Overall treatment time is a critical parameter which determines treatment 
outcome. Loss of local control and survival of 1% per day when treatment 
exceeded 52 days has been reported in studies [13]. 
10. HPV Genotype: There is controversial data in the literature regarding the 
relationship of HPV genotype to prognosis in cervical cancer. However recent 
evidence suggests that HPV 18 positive cancers are associated with poor 
prognosis [14]. Elucidation of the mechanism involved in such association could 
lead to newer treatment approaches.  
 
HOST FACTORS  
1. Lower socioeconomic status: Lower socioeconomic status and poorer survival 
has been associated from several studies. Poverty and lower education has been 
associated with increased cervical cancer mortality [15]. 
2. Hemoglobin levels: In multivariate analysis, lower hemoglobin status at the time 
of diagnosis was associated with worse overall and disease free survival. The 
impact of declining hemoglobin level during Radiotherapy on the final outcome 
was not observed in multivariate analysis [16].  
3. Smoking is a predictor of worse overall survival in patients with locally advanced 
cervical cancer treated with chemoradiation. Median survival was found to be 15 
months shorter for smokers. Smoking was linked to increased cervical cancer 
mortality in 3 of 5 survival analysis. A recent report found that smokers with high 
risk HPV positive cervical cancers were four times more likely to die of cervical 
cancer [9]. 
Recommended follow-up  
• Every 3 months for two years or more often if clinically indicated. 
• Every 4-6 months thereafter.  
• Annually afterwards.  
• Investigations in addition to gynaecological examination should be performed 
depending on symptoms, local findings and general condition of the patient  
 
 
 
 
 
 
 
 
 
 
 
  
LITERATURE REVIEW 
Cervical carcinoma remains among the most common and lethal malignancies in 
women world over [17]. In early stages of the disease, surgery and radiation are equally 
effective treatment modalities conferring good results [18]; but by themselves, these 
treatment modalities in locally advanced cases are suboptimal. The most common 
failures are pelvic with or without systemic relapses.  
In the last decade, seven of eight prospective randomized phase III trials (18 – 22) have 
shown that concurrent chemoradiation is superior to standard radiation alone in bulky 
and locally advanced cervical cancers making it the new standard of care in the 
treatment of this group of cervical cancers. 
Despite these recent encouraging results of concomitant chemoradiation based on 
cisplatin [18 - 22] or other radio sensitizing drugs  there has been a high rate of disease 
recurrences  -  most commonly pelvic sometimes with distant metastases[20, 21]. This 
fact emphasizes the need to try newer treatment modalities to improve survival both 
overall and disease free.  
Neoadjuvant chemotherapy is used in several solid tumors like breast and ovary but in 
cervical carcinoma its role still remains experimental. This may be due to the initial 
setback seen with this modality in the management of cervical cancer where the local 
treatment modality used after the chemotherapy was radiotherapy. The results of this 
sequence of treatment were not very promising and neoadjuvant chemotherapy took a 
back seat. Thus the local treatment modality used after induction chemotherapy is 
important. 
 Despite the fact that there is a lack of randomized trials comparing radiation upfront 
with radical surgery after neoadjuvant chemotherapy, emerging data from trials suggest 
that surgery may be a better modality after chemotherapy as it bypasses the cross-
resistance between chemotherapy and radiation [23,24]. Furthermore both radiotherapy 
and chemotherapy function by first order kinetics while surgery works with zero order 
kinetics and eliminates residual disease in totality. 
 
Several phase III randomized trials have demonstrated the superiority of neoadjuvant 
chemotherapy and surgery over radiation alone [24–28]. In a large, Italian, prospective 
study (29), patients with locally advanced cervical cancer were randomized   received 
neoadjuvant chemotherapy followed with surgery or to standard treatment with definitive 
radiation. There was a 10% - 15% survival advantage among patients who had 
neoadjuvant therapy followed with surgery. Patients with tumors sized less than 4 cm 
did not appear to benefit from this approach as these were amenable to radical 
resection even at presentation. 
 
 But now considering the fact that concurrent chemoradiation is superior to radiation 
alone [18], neoadjuvant chemotherapy needs to compared with concurrent 
chemoradiation. Awaiting confirmation from phase III trials, two phase II studies that 
compared neoadjuvant chemotherapy followed with surgery versus standard 
chemoradiation have reported that both these modalities are similar in terms of survival 
[29]. 
Neoadjuvant chemotherapy looks to be a good alternative to surgery and irradiation for 
initial treatment of locally advanced cervical cancer. The potential benefits of this 
approach are:  
i. It eradicates micrometastases 
ii. Debulks tumors 
iii. Renders inoperable tumors (international federation of gynecology and obstetrics 
[figo] stages ib2, iia2, iib to iiib) operable without  radiotherapy 
iv. Radiotherapy may be kept in reserve as salvage if  a pelvic recurrence occurs 
v. Surgery can overcome the cross-resistance that occurs between chemotherapy 
and radiation when they are delivered sequentially 
This aspect of downstaging disease without irradiation is attractive and offers a totally 
new philosophy of treatment for locally advanced cervical cancer. 
 
Resectability of locally advanced cervical tumors depends on the response to induction 
chemotherapy as seen from various studies [30]. The benefit of neoadjuvant 
chemotherapy on survival in solid tumors is mostly seen in cases with complete clinical 
or pathological response after the chemotherapy. The employment of an effective 
regimen of chemotherapy is thus necessary to obtain better survival figures [26–28].  
 
Alessandro Buda et al (31)  from the Istituto "Mario Negri, Milan compared 2 regimes of 
taxol , ifosfamide and platin( TIP) versus ifosfamide and platin (IP) alone and found that 
The former  regimen was associated with higher response rates than the latter regimen. 
There was no statistically significant effect on overall survival. They reported that a 
significant prognostic factor for survival was the optimal pathologic response. 
A trial is undergoing using 4-epidoxorubincin which is active against advanced or 
recurrent cervical cancer. It was given before and after treatment for a total of six 
courses. Other chemotherapeutic regimens like cis-platinum alone or in combination 
with bleomycin and/or methotrexate have been shown to be effective in reducing the 
primary tumour bulk.(29, 30)  Park et al. gave cis-platinum and 5-flurouracil before 
radiotherapy treatment of patients with poor prognostic factors and showed better 
survival in the neoadjuvant chemotherapy group. Randomized control studies are 
required to decide on the usefulness of neoadjuvant chemotherapy and on the best 
chemotherapeutic regimen. 
Linghu  et al ( 32) from , First Affiliated Hospital, Chongqing, China  investigated on one 
hundred and forty-five patients with cervical squamous cancer stages Ib-IIa , among 
which 17 patients with bulky tumors (> or = 4 cm) were treated with cisplatin-based 
chemotherapy for 1-2 courses followed with radical hysterectomy and pelvic 
lymphadenectomy. The change of tumor size, pelvic lymph nodes metastasis, cervical 
wall invasion, the involvement of surgical specimen margin, and the blood loss during 
operation were assessed after operation and compared with those in 51 patients with 
bulky tumors and 77 patients with small local tumors who underwent surgery directly. 
Their study showed that  
 (1) The tumor size of 17 patients in the first group was decreased in various degrees 
after chemotherapy, with 13 patients of clinical effectiveness (76.47%).  
(2) Post-operative histology has showed that patients with bulky disease have higher 
incidence of lymph node metastasis and deep cervical infiltration (5/68 and 3/68, 
respectively) than small tumors (1/77 and 1/77, respectively).  
(3) Blood loss during operation in preop chemotherapy group was less than upfront 
surgery.  
These authors concluded that most patients with bulky early stage cervical squamous 
carcinoma were sensitive to cisplatin-based chemotherapy, which was effective in 
greatly reducing local tumor size which in turn facilitated surgery by reducing blood loss. 
 
Tanaka et al (33) from Wakayama Medical University, Japan studied preoperative 
irinotecan HCl (CPT-11) chemotherapy in patients with unresectable Stage IIIb cervical 
carcinoma. All 11 patients showed partial responses in tumor size reduction, and radical 
hysterectomy could be successfully performed in ten patients treated with CPT-11 and 
mitomycin C (MMC). One had retroperitoneal cancer progression during chemotherapy. 
Chen H et al (34) of Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, 
China studied the efficacy of Neoadjuvant chemotherapy with short cycle-length, high-
dose agents for locally advanced cancer cervix. They reported that preoperative 
neoadjuvant chemotherapy was well tolerated and was useful to reduce tumor size, 
eliminate pathological risk factors, and improve prognosis in responders 
Hong-Bing Cai (35) ,et al from Zhong Nan Hospital, Wuhan University, China did a trial 
of 106 women with cervical cancer stage IB  who received either neoadjuvant 
chemotherapy (n = 52) or underwent primary surgery (n = 54). The clinical response 
rate was 84.6% including a complete response (CR) in four patients (7.7%), partial 
response (PR) in 40 patients (76.9%), and stable disease (SD) in eight patients 
(15.4%). Surgery showed positive nodes in 9.6% neoadjuvant chemotherapy group 
patients and in 29.6%  of the primary surgery group patients (P = 0.014). Similar results 
were seen with vascular space involvement: 27.8% in the primary surgery arm 
compared with 9.6% in the neoadjuvant chemotherapy group (P = 0.024). Parametrial 
infiltration was seen in 7.4% of the patients in the primary surgery arm, while only 3.8% 
showed it in the neoadjuvant chemotherapy arm (P = 0.679). The 5-year survival rate 
was significantly higher for all patients who received neoadjuvant chemotherapy 
(84.6%) than for the control group (75.9%) (P = 0.0112). These authors concluded that 
neoadjuvant chemotherapy can be used to effectively eliminate pathological risk factors 
thus improving long-term survival in patients with locally advanced cervical cancer. 
Mori T, Hosokawa K, Sawada M et al(35) from Kamigyo-ku, Kyoto, Japan studied 30 
patientswith cervical cancer stage IB2 to IIIB  who received paclitaxel (60 mg/m) and 
carboplatin (area under the curve, 2) every week for 6 cycles. Radical hysterectomy 
was performed 6 days after the final cycle of neoadjuvant chemotherapy. These 
patients were followed up, and the 5-year progression-free survivals (PFS) and overall 
survivals (OS) analyzed.  The 5-year PFS and OS for patients were 79.2% and 83.1%, 
respectively, which were comparable to the outcomes of concurrent chemoradiation 
therapy. Larger tumor size and lymph node metastasis negatively correlated with 
survival. They concluded that preoperative chemotherapy with paclitaxel and 
carboplatin on a weekly schedule followed with radical surgery for patients with locally 
advanced cervical cancer is a promising mode of therapy that may improve the 
prognosis 
35 patients with stage Ib, IIa, and IIb  bulky carcinoma of cervix (> 4 cm) were treated 
with preoperative chemotherapy using a combination of  vinblastine, bleomycin, and cis-
platinum (VBP, 1 - 5 courses) followed with radical surgery at the School of Medicine, 
The Hanyang University, Seoul, Korea by Doo Sang Kim M.D et al.(37). The 
effectiveness of the chemotheapy was evaluated in the surgical specimen. The 
response rate was 89% and included a complete response in 16 patients (46%) and 
partial response in 15 (43%). There was no difference in the response rate by age, 
stage, or the geographic contour of the tumor. The number of courses of chemotherapy 
correlated with the response of the primary tumor (P = 0.0004) up to a maximum three 
courses. In 15 patients with stage IIb, 11 patients (73%) had a stage-down. Lymphnode 
metastases were found in 26% of the patients after chemotherapy. All nodal metastases 
were seen in patients who had a partial response or a stable disease, and none in 
patients with complete responses (P = 0.0029). This study suggested that preoperative 
chemotherapy before surgery was effective in reducing tumor volume or stage offering 
better conditions for surgery, and maybe eliminating micro metastases and  disease in 
lymph nodes and possibly. The authors suggested that preoperative chemotherapy was 
effective  
(1) In reducing tumor volume or the stage of the disease,  
(2) In curing the lymph node involvement, and  
(3) In improving the 2-year tumor-free survival rate. 
 
 
 
Current status of Neoadjuvant chemotherapy in carcinoma cervix: 
Neoadjuvant chemotherapy before surgery is an accepted treatment for locally 
advanced stages of cervical cancer in many parts of the world. The advantage of 
chemotherapy in these patients is  
i. The potential significant reduction in tumor burden, 
ii. Facilitating surgical excision in previously inoperable tumors. 
iii. This approach also may obviate the need for radiation therapy if surgical margins 
are negative 
This may become the standard of care in regions of the world where radiotherapy 
facilities are limited. Trials of neoadjuvant chemotherapy have also demonstrated an 
increased effectiveness without increases in surgical complication rates. (22, 23, 38, 
39). Response of the tumor to chemotherapy is an important prognostic factor for 
survival. (30)  
 The optimal chemotherapy regimen is yet to be defined.  
 
 
 
 
  
AIM OF THE STUDY 
Aims of this study were  
 
1. To assess the efficacy of neoadjuvant chemotherapy followed with radical 
hysterectomy as an alternative to irradiation in bulky carcinoma cervix  
2. To compare 2 two drug regimens- (Paclitaxel and Cisplatin with 5FU and 
cisplatin)   
3. To assess if pathologic response has prognostic value on survival. 
 
 
 
 
 
 
 
 
 
  
PATIENTS AND METHODS 
Eligibility and Random Assignment: 
Patients with histologically confirmed bulky cervical Squamous cell carcinoma (FIGO 
stage IB2 to IIB) were included in the study. 
Pretreatment evaluation included  
1. History,  
2. Physical examination,  
3. Biopsy, 
4. Complete blood analysis,  
5. Chest x-ray and  
6. Examination under anesthesia.  By two examiners, with a third examiner to reach 
a consensus in case  of disagreement  
7. Tumor imaging by means of ultrasound of the abdomen and pelvis and contrast 
enhanced CT of the pelvis to determine the extent of disease. 
8. Tumors involving the anterior fornix were evaluated with a cystoscopic 
examination and tumors involving the posterior fornix with proctoscopic 
examination based on findings on examination under anesthesia. 
 
Inclusion criteria:  
i. Age 18–65 years;  
ii. Karnofsky performance status of ≥70%;  
iii. Stages IB2( bulky IB- >4cm) ,IIA2( bulky IIA - >4cm) and IIB (parametrial 
involvement short of pelvic side wall) 
iv. Normal hematological and renal function: hematological, Hb ≥10 g/l (patients 
were transfused to reach this hemoglobin); leukocytes more than 4000/mm3; 
platelets more than 100000/mm3; and normal blood urea and creatinine;  
v. A normal chest x-ray 
vi. No para aortic nodes or other secondaries on CECT abdomen 
 
Exclusion ciriteria:  
i. Other histologies, such as adenocarcinoma, adenosquamous carcinoma, 
neuroendocrine small cell carcinoma, lymphoma, sarcoma and other rare 
histologies 
ii. Stages IA, IB1, III and IV 
iii. Severe or uncontrolled infection or other systemic diseases 
iv. Concomitant treatment with any experimental drug 
v. Pregnant or nursing women 
vi. Mental illness 
vii. Previous or concomitant malignant diseases other than non-melanoma skin 
cancer 
 
Neoadjuvant Chemotherapy Regimens: 
The patients who were evaluated and found fit for the protocol (adhering to all the 
inclusion criteria and excluding all exclusion criteria) were randomized to either 
of the two chemotherapy regimens 
 The Taxol +Platin regimen was administered as follows: Paclitaxel given at the dose of 
175 mg/m2 as a 3-hour infusion on day 1. Premedication given to reduce the risk of 
Paclitaxel hypersensitivity was as follows: Dexamethasone 8 mg intravenously 60 
minutes before and chlorpheniramine 10 mg, Ondansetron 8mg and Ranitidine 150 mg 
intravenously 30 minutes before treatment delivery. Cisplatin 75 mg/m2 was be  
administered on day 2 as a 60-minute infusion after prehydration with 1 L of normal 
saline  and premedication with Dexamethasone 8 mg intravenously 60 minutes before 
and Ondansetron 8mg and Ranitidine 150 mg  intravenously 30 minutes before 
treatment delivery . Hydration with 3 L of 5% dextrose solution during 24 hours was 
infused simultaneously. 
The 5 Fluoro uracil + cisplatin regimen was administered as follows: 5-Fluoro uracil at a 
dose of 500mg/m2 as a 3- hour infusion. Premedication given to reduce the risk of 5-FU 
toxicity was as follows: Dexamethasone 8 mg intravenously 60 minutes before and 
Ondansetron 8 mg and Ranitidine 150 mg intravenously 30 minutes before treatment 
delivery. Cisplatin 75 mg/m2 was administered on day 2 as a 60-minute infusion after 
prehydration with 1 L of normal saline and premedication with Dexamethasone 8 mg 
intravenously 60 minutes before and Ondansetron 8mg and Ranitidine 150 mg 
intravenously 30 minutes before treatment delivery followed by post-hydration with 1 L 
of 5% dextrose solution over 2 hours.  
In both arms, treatment was administered every 3 weeks for a total of three courses. 
  
Treatment Modifications 
 
Complete Blood Counts were   performed 3 weekly or more often if toxicity occurred; 
evaluation of renal function was repeated before each cycle.  
Treatment administration was based on evaluation of hemoglobin and blood cell counts 
before the start of each cycle. Treatment was administered only if the Hemoglobin was 
more than 10g/dl, Total WBC Count was more than 4000/µL and the platelet count more 
than 100,000/µL. Treatment was delayed week to week until minimum hematologic 
parameters are met. After two consecutive treatment delays, on the basis of physician 
judgment, treatment was either discontinued or continued.  Delays were not permitted 
other than for documented toxicity.  
Treatment after Neoadjuvant Chemotherapy  
Tumor response was assessed clinically (Abdominal, vaginal and Rectal examination) 
and by CT after three courses and all patients with adequate response that was 
deemed operable (with supple parametria, decrease in bulk of cervix and lower two 
thirds of vagina free such that radical hysterectomy maybe done achieving negative 
margins) underwent radical hysterectomy and pelvic lymphadenectomy within 3 or 4 
weeks after the administration of the third cycle.  
 
Radical hysterectomy procedure  
Under general anesthesia, laparotomy was done using a lower midline/vertical incision. 
Lateral pelvic peritoneum was incised, retroperitoneal plane was created and ureters 
were identified. Infundibulo pelvic and round ligament was ligated and divided at the 
pelvic brim. Peritoneal incision was extended anteriorly up to uterovesical fold. Cervico 
vesical septum was identified divided sharply and bladder pushed down away from 
cervix and vagina. Ureters were traced down to Wertheim’s ureteric canal preserving 
mesoureter. Pararectal and paravesical fossae were created by entering the plane 
between pelvic side wall, internal iliac vessels and the ureter down to the levator ani. 
Uterine artery was origin identified and ligated and divided at its origin. Ureteric tunnel of 
parametrium was deroofed and ureter lateralized. Recto vaginal fold of peritoneum was 
opened and recto vaginal space was created down to levator ani. Uterosacral ligaments 
were divided lateral to rectum. Lateral bladder pillars were divided. Parametrium was 
clamped and divided. Vagina was divided with 2- 4 cm cuff. Vault was closed or left 
open as per the surgeons preference. Bilateral pelvic lymphadenectomy was done 
clearing all lympho areolar tissue around iliac vessels and obturator fossa. Hemostasis 
was secured and abdomen was closed in layers.  
 
Post operative care  
Analgesia was ensured with intra muscular Tramadol and epidural Tramadol 
/sensorcaine for 2 days. Orals were started after return of bowel sounds (usually 2nd 
post op day). Patients were mobilized the day after surgery. Urethral catheters were 
retained till 10th postoperative day and clamped intermittently for bladder sensation 
from 7th postoperative day. Post void residual urine was assessed on the 10th day. If it 
was more than 100ml or if the patient developed retention of urine, bladder was 
recatheterized. Bladder training was done and post void residual urine was assessed 
again and catheter was removed after 15 days. Sutures were removed on day 10. 
  
Inoperable patients: 
Patients with tumors that were deemed inoperable because of static disease or 
progression where radical hysterectomy achieving negative margins would not be 
possible after neoadjuvant chemotherapy were treated with radical concurrent chemo 
radiation (cisplatin concurrent with 50 Gy pelvic EBRT and 30 Gy through 
brachytherapy).  
Women with positive nodes, parametrial involvement, cut margins positive after radical 
hysterectomy and pelvic lymphadenectomy were given additional treatment with 
chemoradiotherapy (cisplatin concurrent with 50 Gy pelvic EBRT and 30 Gy through 
brachytherapy).  Patients with disease remaining only in the cervix or vagina with 
negative nodes, no parametrial involvement and all margins negative were treated with 
vault radiation using low dose rate intra cavitary radiation alone. 
 
Evaluation of Response 
The response to neoadjuvant chemotherapy was clinically evaluated after the third 
course and the pathological response was assessed in those patients who underwent 
surgery. 
Responses were registered as follows: 
1. Complete response 
2. Partial response 1 
3. Partial response 2 
4. Static disease 
5. Progressive disease 
 Complete response was registered when no clinical or pathological evidence of 
disease existed. All other cases (persistence or progression) were registered as no 
complete response.  
A complete pathological response to neoadjuvant chemotherapy was registered when 
no evidence of disease (microscopic or macroscopic) existed. 
Partial response 1 was registered when there was a ≥50% reduction in the product of 
the longest perpendicular diameters of the disease and the disease was operable after 
three cycles of chemotherapy with evidence of gross residual disease   
Partial response 2 was a partial response with no gross disease residue but 
microscopic residue only, either in the cervix and/ or the pelvic nodes 
Stable disease was <50% reduction or an increase of <25% in the product of the 
longest perpendicular diameters of the disease making the disease inoperable after 3 
cycles of chemotherapy.  
Progressive disease with a >25% increase or the appearance of new lesions making 
the disease inoperable after 3 cycles of chemotherapy.  
Toxicity Assessment 
 Toxicity was graded according to Common toxicity criteria for adverse effects of the 
National Cancer Institute version 4. 
 
Follow-Up Procedures and Survival: 
Patients were monitored for assessment of disease status 1 month after the end of 
treatment and every 1 month thereafter for the first year and three monthly thereafter. 
During each visit complete and pelvic examinations were performed, as well as blood 
counts, clinical chemistry, ultrasound abdomen and pelvis, vaginal cytology and chest 
X-rays annually. Computed tomography scans, ultrasound and other studies were 
carried out when appropriate.  
 
Statistical Methods 
This was a  randomized, single centre  study aimed at comparing the activity and 
toxicity of Fluorouracil +Platin versus Taxol + Platin  in the neoadjuvant setting for 
patients with bulky squamous cell cervical cancer.  
Randomization was done using permutated block method. 
 
The primary efficacy parameter was the response rates. Secondary end points were 
overall survival and disease-free survival. 
Statistical analysis was performed using SPSS version 16.  
 
The chi-square and t-tests were used when appropriate to compare patient 
characteristics, responses and toxicity. Influence of clinical, pathological and thereupetic 
factors on outcome were assessed using a multivariate analysis with a Cox regression 
model 
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 Case analysis and Results 
 
From September 2010 to February 2013 a total of 61 patients with previously untreated 
cancer cervix stages IB2, IIA2 and IIB fulfilled the criteria for inclusion in this trial. 5 
patients were excluded because one of them developed anaphylaxis to Paclitaxel; 
another developed severe febrile neutropenia after the first cycle of chemotherapy and 
the other three patients defaulted during or after the preoperative chemotherapy. 
Though one of the latter three patients did turn up after one year following three cycles 
of chemotherapy and she had a complete pathologic response on radical hysterectomy 
she was not taken up for the analysis because she didn’t fit into the time frame of the 
protocol. The median follow up period was 12months (range 1 – 28 months). 
 
One other patient who had static disease with preoperative chemotherapy was treated 
with radical chemo radiation and had a residue after chemoradiation. She was surgically 
salvaged with a total pelvic exenteration and continues to be disease free on follow up.  
 
Patient demographics: 
A total of 56 patients were enrolled , of whom  none  were of the 20 – 30 age group,12    
were in the 30 – 39 age group, 25 were in the 40 – 49 age group, 13 were in the 50 – 59 
age group and  6 were in the    60 – 65 age group. The median age was 47years 
(range32 -65 years)  
 
   
 
 
Tumor characteristics: 
Only Squamous cell carcinomas of the uterine cervix were included in this trial. Of the 
56 patients 17 had grade I tumor, 19 had grade II tumor and 20 had grade III tumor. 
Grade of tumor 
Chemo Group 
Total 5FU + Cisplatin Paclitaxel + Cisplatin 
1 8 9 17 
2 10 9 19 
3 11 9 20 
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Chemo Group 
Total 5FU + Cisplatin Paclitaxel + Cisplatin 
1 8 9 17 
2 10 9 19 
3 11 9 20 
Total 29 27 56 
Grade of tumor in the two chemo groups 
 
 
49 had tumor size >4cm and   7 had tumor < 4cm 
   11 had stage IB2 disease, 6 had stage IIA2 disease, and 39 had stage IIB disease. 
 
Stage 
Chemo_Group 
Total 
5FU + Cisplatin Paclitaxel + Cisplatin 
0
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1 2 3 Total
IB 2 4 7 11 
II B 23 16 39 
IIA 2 2 4 6 
Total 29 27 56 
 
  
 Chemotherapy and response
 
 27 Patients received Paclitaxel+ cisplatin 
Cisplatin and 5FU chemotherapy.
Of these 40 patients 15 Patients had a complete pathological response.  23 Patients 
had no macroscopic disease but microscopic residue confined to the cervix alone.  3 
Patients had residue in the pelvic nodes. In the Paclitaxel+ cisplatin chemotherapy 
group 13Patients had a complete pathological response.   8 Patients had no 
macroscopic disease but microscopic residue confined to the cervix alone.    1 Patients 
had residue in the pelvic nodes.
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 In the Cisplatin and 5FU chemotherapy group 1 Patient had a complete pathological 
response. 15 Patients had no macroscopic disease but microscopic residue confined to 
the cervix alone. 2 Patients had residue in the pelvic nodes. 
post_chemo_response Chemo_Group Total 
5FU + Cisplatin Paclitaxel + Cisplatin 
CR 3 12 15 
PR 1 11 6 17 
PR 2 4 4 8 
SD + PD 11 5 16 
Total 29 27 56 
48%
52%
Paclitaxel with cisplatin 
5FU with Cisplatin
  
  14 Patients received no treatment after the radical hysterectomy, while   22 patients 
received intracavitary low dose radiation alone and 3 patients received post operative 
chemoradiation. 
 
Post operative treatment 
Chemo_Group 
Total 5FU + Cisplatin Paclitaxel + Cisplatin 
ICCA only 14 8 22 
Nil 1 13 14 
post op chemo RT 2 1 3 
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 Surgical characteristics: 
40 patients were taken up for radical hysterectomy with bilateral pelvic 
lymphadenectomy after completing three cycles of preoperative chemotherapy, 22  
patients after the Paclitaxel+ cisplatin chemotherapy and 18  patients after the Cisplatin 
and 5FU chemotherapy. 
The average operating time was 132.25 min (range 90 -   mins) with a mean blood loss 
of 320ml. the average parametrial margin obtained on the right was 22.92mm (range 16 
– 28mm) and on the left 22mm (range 14 – 33mm). The nodal yield was an average 
7.97(3-12) on the left and 9(4 – 15) on the right. The mean vaginal cuff obtained was 
30.375mm (range 22 – 38mm). 
Operative characteristics 
Parameter  Mean Median Range 
operating time in  min 132.25  130 90 - 220    
blood loss in ml 319 270 140 - 1400 
parametrial margin – left in mm 21.9 22 14 - 30 
parametrial margin – right in mm  22.8 24 16 - 28 
nodal yield – left 7.92 8 3 - 12 
nodal yield – right 8.92 9 4 - 15 
Vaginal cuff – in mm 30.2 30 22 - 38 
 
 
  
Toxicity of chemotherapy: 
Patients had chemotherapy associated adverse effects.the commonest adverse effect 
were alopecia and vomiting.  31  patients had alopecia, 14  patients had anorexia, 28 
patients had nausea,  31 had vomiting, 6 had allergic reactions, 18 had decreased 
hemoglobin,  2 had decreased neutrophil counts, no patients had decrease in  platelets,  
4 had neuropathy and  1 patient had raised creatinine. . Allergic adverse effects were 
more common in the Paclitaxel and Cisplatin arm compared with the 5 FU and Cisplatin 
arm. There was no other difference in toxicity profiles among the two groups.   
 
Operative and post operative complications: 
Post operative bladder morbidity was the commonest complication.     13 Patients had 
urinary retention, 5 had post operative wound infection, and 3 had operative injury to 
artery / vein. There was no operative injury to rectum/ bowel / bladder/ ureter in any of 
the 40 patients who underwent radical hysterectomy with pelvic lymphadenectomy. 
There was no operative mortality. 
 
Outcome 
There were 2 deaths among the 56 patients. One patient who had carcinoma cervix 
stage IIB and completed 3 cycles of chemotherapy with Cisplatin and 5FU followed with 
a radical hysterectomy and had a partial response (residual macroscopic disease 
confined to the cervix and vagina with no disease in the pelvic node, parametrium or 
margins) followed with low dose intracavitary vault irradiation recurred in the pelvis with 
inoperable disease after three months. She was treated with chemoradiation but 
succumbed to the progressive disease 4 months later. 
One other patient died of an unrelated cause 8 months after treatment. 
With a median follow up of 12 months (range 1 – 29 months) there was only one 
recurrence among all 56 patients. There were no distant failures. 
 
Predictive factors of response 
The chemotherapy group was the only significant factor predicting response, and more 
responses were seen in the Paclitaxel with Cisplatin arm across all groups compared 
with the 5FU and cisplatin arm. 
Chemo_Group 
POST_CHEMO_RESPONSE Total 
CR PR 1 PR 2 SD + PD 
5FU + Cisplatin 3 11 4 11 29 
Paclitaxel + 
Cisplatin 
12 6 4 5 27 
Total 15 17 8 16 56 
 
Chi-Square Test 
 
Value df 
 Significance . 
(2-sided) 
Pearson Chi-Square 9.061 3 .028 
N of Valid Cases 56   
 
 
 
Predictive factors of cervical residue 
Residue in the cervix after chemotherapy was more common in the 5FU and Cisplatin 
arm compared with the Paclitaxel and Cisplatin arm. The responses were complete 
more often in the Paclitaxel and Cisplatin arm 
 
Chemo_group No residual tumor 
Residual SCC involving cervix and 
vagina,parametrium free, margins 
free, nodes ++ 
Residual scc in 
cervix, margins, 
nodes free 
N 
5FU + Cisplatin 2 2 15 19 
Paclitaxel + Cisplatin 13 1 8 22 
Total 14 3 23 40 
 
Chi-Square Test 
 
Value df 
 Significance   
(2-sided) 
Pearson Chi-Square 14.947 3 .002 
N of Valid Cases 40   
 
 
 
 
  
DISCUSSION 
 
Cervical carcinoma remains among the most common and lethal malignancies in 
women world over [17]. In early stages of the disease, surgery and radiation are equally 
effective treatment modalities conferring good results [18]; but by themselves, these 
treatment modalities in locally advanced cases are suboptimal. The most common 
failures are pelvic with or without systemic relapses.  
Neoadjuvant chemotherapy looks to be a good alternative to surgery and irradiation for 
initial treatment of locally advanced cervical cancer. The potential benefits of this 
approach are:  
i. Reduces the size of tumors 
ii. Renders inoperable tumors (international federation of gynecology and obstetrics 
[FIGO] stages IB2, IIA2, IIB TO IIIB) operable without  radiotherapy 
iii. Radiotherapy may be kept in reserve as salvage if  a pelvic recurrence occurs 
iv. Surgery can undo the cross-resistance that occurs between chemotherapy and 
radiation when they are delivered sequentially 
v. It eradicates micrometastases 
 
This aspect of down staging disease without irradiation is attractive and offers a totally 
new philosophy of treatment for locally advanced cervical cancer. 
 
  
Patient characteristics: 
In this study patients in both chemotherapy groups were well matched age wise and 
there was no significant effect of age on the response rates or the adverse effects 
encountered. Grade of the tumor and tumor size also did not have a significant role in 
the responses or the outcomes. 
 
Chemotherapy and response: 
There was a significantly better response rate with the Paclitaxel and Cisplatin 
chemotherapy compared with the Cisplatin and 5FU chemotherapy. More responses 
were complete in the Paclitaxel and Cisplatin chemotherapy arm, and with previous 
studies indicating that the complete responses translated into better survivals, this may 
indicate that this combination may be more efficacious than the Cisplatin and 5FU 
combination. 
 
With the median follow up of 12 months and only one recurrence the disease free 
survival could not be assessed. Longer follow up of these patients may yield more 
interesting insights into the benefit of preoperative chemotherapy in avoiding radiation in 
carcinoma cervix especially in our part of the world with scarce resources where 
carcinoma cervix is still a rampant problem frequently presenting in bulky or advanced 
stages. 
 
 
 
 Surgical characteristics: 
Radical Hysterectomy and bilateral pelvic lymphadenectomy was done in 40 patients 
after achieving an optimal response rendering them operable- with supple parametria 
and non bulky disease with free vaginal margins and the operative characteristics were 
studied.  
The operating times and average blood loss were not significantly increased when 
compared with radical hysterectomy performed upfront in our institute as quoted in 
previous studies. Infact with less fibrosis compared with radiotherapy, the tissues were 
supple and operating times and blood loss was less than when performing radical 
hysterectomy after radiotherapy. The parametrium obtained, the vaginal cuff and the 
nodal yield were all comparable with radical hysterectomy done upfront and were not 
compromised.  
 
Toxicity of chemotherapy: 
With adequate premedication, toxicity of the preoperative chemotherapy was tolerated 
well by most patients. Nausea and vomiting were present only in lower grades and no 
high grade adverse effect requiring intense management was encountered. Allergic 
adverse effects were more common in the Paclitaxel and Cisplatin arm compared with 
the 5 FU and Cisplatin arm, possibly due to the Paclitaxel. The other adverse effects 
were well matched in both groups. 
 
  
Operative and post operative complications: 
Operative complications were not significantly increased in the patients who underwent 
radical hysterectomy after preoperative chemotherapy. No bladder/ ureter/ bowel/ rectal 
injuries were encounterd in any of the patients. However there was a small increase in 
injury to arteries or veins, in one case with significant exsanguinations requiring 
transfusion, but none required reconstruction or bypass (that is grade 2 and less).This 
may possibly indicate a response of the nodes to chemotherapy with a reaction 
rendering them adherent to the vasculature leading to injuries. But with adequate 
surgical expertise in a centre performing large volumes of pelvic surgeries this was not 
a problem to face at the cost of increased complete responses. 
 
Outcome: 
Of 56 patients, 40 patients could be taken for surgery after preoperative chemotherapy 
and of these 40 only 3 required post operative chemo radiotherapy. 14 Patients 
received no treatment after the radical hysterectomy, while   22 patients received 
intracavitary low dose radiation. Thus radiotherapy was totally avoided in 14 patients 
and only small dose of intracavitary radiation was required in 22 patients (a total of 36 of 
the 56 patients) who would have traditionally been managed with chemoradiation or 
radiation and surgery. This presents an attractive option in management of carcinoma 
cervix in resource scarce countries at the same time avoiding the morbidity of radiation 
in this group of patients. 
 
 
CONCLUSION 
 
1. Preoperative chemotherapy in carcinoma cervix is effective in reducing tumor 
volume and the stage of the disease making bulky stage IB, IIA and IIB disease 
operable. It may present an attractive option in patients with bulky inoperable 
tumors of the cervix avoiding radiation and keeping it in reserve for the salvage of 
recurrences. 
2. Paclitaxel with cisplatin yields better response rates (more complete responses) 
than 5FU and cisplatin and maybe a better drug combination for preoperative 
chemotherapy in carcinoma cervix. 
3. Neoadjuvant chemotherapy with Paclitaxel and cisplatin followed by radical 
surgery for patients with bulky inoperable cervical Squamous cell carcinoma is a 
promising mode of treatment that may improve the prognosis. The response 
rates were good, but longer term follow up is required to assess the benefit on 
survival and disease free rates. It would be worthwhile to conduct larger-scale 
trials with a longer follow up for comparison with the results of the 
chemoradiation therapy study. 
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1 G 38 1082/10 2 nil 1 2 nil 2 nil nil nil nil nil nil nil nil nil nil RCO ICCA 28
2 M 42 1121/10 2 nil 2 2 2 nil nil nil nil nil nil nil nil 1 nil nil 26
3 L 50 1330/10 2 1 1 1 nil 1 nil nil nil nil nil nil nil nil nil nil RCO ICCA 29
4 M 45 1329/10 2 nil 2 2 1 nil nil nil nil nil nil nil nil nil nil nil RCO ICCA 27
5 V 37 1421/10 nil 1 2 2 nil 2 nil nil nil nil nil nil nil nil nil nil RCO ICCA 7 +
6 A 55 1506/10 nil 1 2 1 nil 3 nil nil nil nil nil nil nil nil nil 1 RCO ICCA 22
7 S 56 1547/10 2 nil nil 1 nil 2 1 nil 2 nil nil nil nil nil nil 2 NR nil 20
8 D 38 30/11 2 nil 2 2 nil nil nil nil nil nil nil nil nil nil nil 2 RCO ICCA 18
9 Y 38 198/11 nil 2 2 2 nil 1 nil nil nil nil nil nil nil nil nil nil 16
10 V 66 295/11 1 nil nil nil nil 2 nil nil nil nil nil nil nil nil nil 1 RCO ICCA 16
11 K 34 297/11 nil nil 1 nil nil 2 nil nil nil nil nil nil nil nil nil nil RCO ICCA 14
12 P 35 311/11 nil 1 2 2 nil 1 nil nil nil nil nil nil nil nil nil nil 15
13 S 40 370/11 nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil NR nil 18
14 D 36 406/11 nil 1 1 2 nil 2 nil nil nil nil nil nil nil nil nil nil 14
15 S 50 432/11 1 nil 1 1 nil 1 nil nil nil nil nil nil nil nil nil 1 RCO ICCA 19
16 V 50 531/11 2 nil nil nil nil nil nil nil 1 nil nil nil nil 1 nil nil RCO ICCA 11
17 T 40 541/11 nil 1 nil nil nil nil nil nil nil nil nil nil nil nil nil nil 17
18 D 47 731/11 2 nil nil nil nil 1 1 nil nil nil nil nil nil nil nil nil NR nil 18
19 S 47 854/11 nil nil 1 1 nil nil nil nil nil nil nil nil nil nil nil nil 16
20 L 55 932/11 nil 1 1 1 1 nil nil nil nil nil nil nil nil nil nil nil RCO ICCA 14
21 S 65 972/11 2 nil nil nil nil nil nil nil nil nil nil nil nil nil 2 nil RNP CRT 15
22 S 32 1000/11 2 1 1 1 nil nil nil nil nil nil nil nil nil nil 3 2 NR nil 15
23 M 48 1033/11 nil nil 1 1 nil nil nil nil nil nil nil nil nil nil nil nil RCO ICCA 14
24 L 37 1066/11 2 nil 1 1 nil nil nil nil nil nil nil nil nil nil nil nil 12
25 B 45 1178/11 nil nil 1 1 nil nil nil nil nil nil nil nil nil nil nil nil RNP CRT 15
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26 M 40 1177/11 2 nil 2 1 nil nil nil nil nil nil nil nil nil nil nil nil NR nil 13
27 S 50 1162/11 nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil 2 12
28 M 50 1182/11 2 nil nil nil nil nil nil 1 nil nil nil nil nil nil nil nil RCO ICCA 12
29 S 48 1195/11 nil nil nil nil nil nil nil nil 2 nil nil nil nil nil nil nil NR nil 11
30 N 52 1308/11 nil nil 1 1 nil nil nil nil nil nil nil nil nil nil nil nil 11
31 M 52 1317/11 1 1 1 1 nil nil nil nil nil nil nil nil nil nil nil nil 10
32 K 38 1347/11 nil nil nil nil nil nil nil nil nil nil nil nil nil nil 1 1 RCO ICCA 10
33 A 41 1348/11 1 Nn nil nil nil nil nil nil nil nil nil nil nil nil nil nil RCO ICCA 13
34 M 40 1386/11 1 nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil NR nil 12
35 M 63 1376/11 2 nil nil 1 nil nil 1 nil nil nil nil nil nil nil nil nil RCO ICCA 11
36 V 61 34/12 nil 1 1 1 nil nil nil nil nil nil nil nil nil nil 2 1 RCO ICCA 12
37 K 48 266/12 nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil RCO ICCA 9
38 V 40 287/12 1 nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil NR nil 7
39 P 58 313/12 2 nil 1 1 nil nil nil nil nil nil nil nil nil nil nil 1 NR nil 7
40 V 48 331/12 nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil NR nil 9
41 P 42 432/12 2 nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil 8
42 L 45 525/12 nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil RCO ICCA 7
43 L 55 639/12 2 nil 1 1 nil nil nil nil nil 1 nil nil nil nil nil 1 7
44 S 55 739/12 2 nil nil nil nil 1 nil nil 2 nil nil nil nil nil nil nil NR nil 4
45 T 43 763/12 2 nil nil 1 1 nil nil nil nil nil nil nil nil nil nil nil NR nil 4
46 V 48 854/12 2 nil nil nil nil nil 1 nil nil nil nil nil nil nil nil nil RNP CRT 3
47 V 36 873/12 nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil RCO ICCA 3
48 M 36 1016/12 nil nil 1 nil nil nil nil nil nil nil nil nil nil 2 3 nil NR nil 2
49 A 47 1050/12 2 nil 1 nil nil nil nil nil nil nil nil nil nil nil nil nil 4
50 J 48 1076/12 nil 1 3 2 nil nil 1 1 nil nil nil nil nil nil nil nil 4
51 S 46 1077/12 1 nil nil nil nil nil nil nil nil nil nil nil nil nil nil 3
52 A 40 1081/12 2 nil nil 1 nil nil nil nil nil nil nil nil nil nil nil nil 3
53 M 60 1085/12 nil nil 1 2 nil 1 nil nil nil nil nil nil nil nil nil 2 NR nil 2
54 M 62 1095/12 1 grade nil 1 1 nil 1 nil nil nil nil nil nil nil nil nil 3
55 A 42 2008/12 1 nil nil nil nil nil nil nil nil nil nil nil nil nil nil nil 1
56 L 52 2014/12 nil nil 1 1 nil nil nil nil nil nil nil nil nil nil nil nil 1
